[go: up one dir, main page]

WO2004031160A3 - Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete - Google Patents

Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete Download PDF

Info

Publication number
WO2004031160A3
WO2004031160A3 PCT/FR2003/002904 FR0302904W WO2004031160A3 WO 2004031160 A3 WO2004031160 A3 WO 2004031160A3 FR 0302904 W FR0302904 W FR 0302904W WO 2004031160 A3 WO2004031160 A3 WO 2004031160A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
compounds
thiohydantoine
diabetes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002904
Other languages
English (en)
Other versions
WO2004031160A2 (fr
Inventor
Jean Binet
Benaissa Boubia
Evelyne Chaput
Alan Edgar
Khan Ou
Philippe Ratel
Soth Samreth
Didier Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0212370A external-priority patent/FR2845385B1/fr
Priority claimed from FR0212368A external-priority patent/FR2845383B1/fr
Priority claimed from FR0212369A external-priority patent/FR2845384B1/fr
Priority to JP2004540883A priority Critical patent/JP2006510600A/ja
Priority to AU2003279442A priority patent/AU2003279442A1/en
Priority to EP03772390A priority patent/EP1546111A2/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to CA002500977A priority patent/CA2500977A1/fr
Priority to US10/529,817 priority patent/US20060025589A1/en
Publication of WO2004031160A2 publication Critical patent/WO2004031160A2/fr
Publication of WO2004031160A3 publication Critical patent/WO2004031160A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la 2-thiohydantoïne choisis parmi les composés de formule générale (I): dans laquelle notamment l'un des radicaux R1 ou R2 comprend dans la structure deux noyaux aromatiques ou représente le groupe dibenzofuranyle, R3 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C1-C4, un groupe alcoxy en C1-C4, un groupe hydroxy, un groupe phényle ou un groupe benzyle, R4 représente un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1-C4, et leurs sels d'addition avec un acide non toxique, notamment les sels pharmaceutiquement acceptables. Elle concerne également leur procédé de préparation, les compositions pharmaceutiques les contenant, et leur utilisation en tant que substance pharmacologiquement active, notamment dans le cas du traitement du diabète, des maladies dues à une hyperglycémie, des hypertriglycéridémies, des dyslipidémies ou de l'obésité.
PCT/FR2003/002904 2002-10-01 2003-10-03 Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete Ceased WO2004031160A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
CA002500977A CA2500977A1 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
JP2004540883A JP2006510600A (ja) 2002-10-04 2003-10-03 ２−チオヒダントインに由来する化合物及び治療におけるその使用
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
EP03772390A EP1546111A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR0212370A FR2845385B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR0212369A FR2845384B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR0212368A FR2845383B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR02/12370 2002-10-04
FR02/12369 2002-10-04
FR02/12368 2002-10-04

Publications (2)

Publication Number Publication Date
WO2004031160A2 WO2004031160A2 (fr) 2004-04-15
WO2004031160A3 true WO2004031160A3 (fr) 2004-05-27

Family

ID=32073876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002904 Ceased WO2004031160A2 (fr) 2002-10-01 2003-10-03 Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete

Country Status (6)

Country Link
US (1) US20060025589A1 (fr)
EP (1) EP1546111A2 (fr)
JP (1) JP2006510600A (fr)
AU (1) AU2003279442A1 (fr)
CA (1) CA2500977A1 (fr)
WO (1) WO2004031160A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10322108B4 (de) * 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
NZ548209A (en) 2003-12-19 2009-07-31 Univ California Methods and materials for assessing prostate cancer thearapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
RU2448096C3 (ru) 2005-05-13 2017-12-11 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилгидантоины
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007126765A2 (fr) 2006-03-27 2007-11-08 The Regents Of The University Of California Modulateur de récepteur androgène pour le traitement du cancer de la prostate et de maladies associées au récepteur androgène
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
WO2009097998A1 (fr) * 2008-02-07 2009-08-13 Sanofi-Aventis Imidazolidine-2,4-diones substitués par un arylchalcogeno-arylalkyle, procédé de production, médicaments contenant ces composés et leur utilisation
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
KR101456994B1 (ko) * 2009-09-10 2014-11-04 통유지 안드로겐 수용체 길항제 및 그의 용도
JP2014500038A (ja) * 2010-12-23 2014-01-09 デュポン ニュートリション バイオサイエンシーズ エーピーエス 殺菌性組成物
PL2683694T3 (pl) 2011-03-10 2016-10-31 Antagoniści receptora androgenowego i ich zastosowania
SI2894151T1 (sl) 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3079135A1 (fr) 2017-10-16 2019-04-25 Arturo Molina Anti-androgenes destines au traitement du cancer de la prostate resistant a la castration, non metastatique
CN113831337B (zh) * 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2839403A (en) * 1955-08-30 1958-06-17 Eastman Kodak Co Merocyanine dyes and photographic emulsions containing them
EP0002259A2 (fr) * 1977-12-01 1979-06-13 The Wellcome Foundation Limited Dérivés de l'hydantoine et leurs sels, leur synthèse et leurs compositions pharmaceutiques
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
EP0580459A1 (fr) * 1992-07-08 1994-01-26 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
WO1997019932A1 (fr) * 1995-11-28 1997-06-05 American Home Products Corporation Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
EP0721944B1 (fr) * 1994-07-29 2001-01-17 Suntory Limited Derives d'imidazolidine et son utilisation
WO2001016122A1 (fr) * 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzelidene-thiazolidinediones et leurs analogues, utilises dans le traitement du diabete

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2839403A (en) * 1955-08-30 1958-06-17 Eastman Kodak Co Merocyanine dyes and photographic emulsions containing them
EP0002259A2 (fr) * 1977-12-01 1979-06-13 The Wellcome Foundation Limited Dérivés de l'hydantoine et leurs sels, leur synthèse et leurs compositions pharmaceutiques
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
EP0580459A1 (fr) * 1992-07-08 1994-01-26 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0721944B1 (fr) * 1994-07-29 2001-01-17 Suntory Limited Derives d'imidazolidine et son utilisation
WO1997019932A1 (fr) * 1995-11-28 1997-06-05 American Home Products Corporation Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
WO2001016122A1 (fr) * 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzelidene-thiazolidinediones et leurs analogues, utilises dans le traitement du diabete

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOZDAG O. ET AL.: "synthesis and hypoglycemic activity of some new flavone derivatives", ARZNEIMITTEL FORSCHUNG, vol. 50, no. 7, July 2002 (2002-07-01), pages 626 - 630, XP001146886 *
SOLIMAN R. ET AL.: "preparation and antidiabetic activity of cyclic sulfonylthiourea derivatives", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 70, no. 8, 1981, pages 952 - 956, XP001146887 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof

Also Published As

Publication number Publication date
EP1546111A2 (fr) 2005-06-29
WO2004031160A2 (fr) 2004-04-15
CA2500977A1 (fr) 2004-04-15
JP2006510600A (ja) 2006-03-30
US20060025589A1 (en) 2006-02-02
AU2003279442A1 (en) 2004-04-23
AU2003279442A8 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
WO2004031160A3 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
TW200833675A (en) Nicotinamide derivatives
EA201070202A1 (ru) Производное оксопиразина и гербицид
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MY126489A (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
WO2008140099A1 (fr) Dérivés de tétrazoyl-oxime et agent de lutte contre une maladie végétale
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
AU4396899A (en) Remedies for diabetes
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2004096761A8 (fr) Derives d'oxyphenyl aromatique et de sylfanylphenyl aromatique
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
EA200600878A1 (ru) Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar )
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20076000L (no) Aminosyrederivater
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
DE50304891D1 (de) N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2006025589

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10529817

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2500977

Country of ref document: CA

Ref document number: 2003772390

Country of ref document: EP

Ref document number: 2004540883

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003772390

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10529817

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003772390

Country of ref document: EP